INmune Bio (NASDAQ:INMB) Stock Price Down 2.4% – Time to Sell?

INmune Bio, Inc. (NASDAQ:INMB) traded down 2.4% during mid-day trading on Friday . The stock traded as low as $1.24 and last traded at $1.24. 150,547 shares traded hands during mid-day trading, a decline of 53% from the average session volume of 322,965 shares. The stock had previously closed at $1.27.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Lucid Cap Mkts raised shares of INmune Bio from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 11th. Wall Street Zen lowered shares of INmune Bio from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $8.00.

INmune Bio Stock Down 2.4%

The company’s 50 day moving average price is $1.37 and its 200 day moving average price is $1.48. The firm has a market capitalization of $32.96 million, a price-to-earnings ratio of -0.74 and a beta of 1.03.

INmune Bio (NASDAQ:INMB) last posted its earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in INmune Bio by 3.4% during the third quarter. Vanguard Group Inc. now owns 876,292 shares of the company’s stock valued at $1,814,000 after purchasing an additional 28,541 shares during the period. Geode Capital Management LLC lifted its position in INmune Bio by 6.9% during the second quarter. Geode Capital Management LLC now owns 389,931 shares of the company’s stock valued at $901,000 after purchasing an additional 25,069 shares during the period. State Street Corp lifted its position in INmune Bio by 22.3% during the fourth quarter. State Street Corp now owns 347,259 shares of the company’s stock valued at $542,000 after purchasing an additional 63,426 shares during the period. JPMorgan Chase & Co. lifted its position in INmune Bio by 1,042.7% during the second quarter. JPMorgan Chase & Co. now owns 73,097 shares of the company’s stock valued at $169,000 after purchasing an additional 66,700 shares during the period. Finally, XTX Topco Ltd lifted its position in INmune Bio by 41.3% during the fourth quarter. XTX Topco Ltd now owns 68,865 shares of the company’s stock valued at $107,000 after purchasing an additional 20,121 shares during the period. 12.72% of the stock is currently owned by institutional investors and hedge funds.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.